Blackmores Institute

Company snapshot

Blackmores Institute is the academic and professional arm of Blackmores. An authority in natural health, we deliver high quality, evidence-based, natural medicine research, education and information. Join our online community at our website for healthcare professional access to accredited complementary medicine education, interactions information and a weekly complementary medicine news and resear

• 1 approved product(s) across US/EU regulatory metadata.
• 17 active pipeline program(s) linked via ClinicalTrials.gov.
• 38 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Blackmores Institute. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Blackmores Institute.

1. Jun 8, 2026 Clinical update

   ZKSJ0132 — Unknown

2. Jun 8, 2026 Clinical update

   GARM-Autism Adults — Phase 2

3. Jun 8, 2026 Clinical update

   silevertinib in combination with temozolomide — Phase 2

4. Jun 8, 2026 Clinical update

   Normal Saline (NS) .9% 10 mL Injection — Phase 1

5. Jun 8, 2026 Clinical update

   Liposomal bupivacaine — Approved

View all clinical trial activity →

• What is Blackmores Institute?

  Blackmores Institute is a pharma organization headquartered in Warriewood, AU. Primary therapeutic focus areas include Peripheral Artery Disease, Muscle-Invasive Bladder Carcinoma, Therapeutic Equivalency, Solid Tumor, Atherosclerosis. NovaPharmaNews links 17 clinical program(s),

• Is Blackmores Institute publicly traded?

  Blackmores Institute appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Blackmores Institute develop or market?

  We link 24 drug profile(s) where Blackmores Institute is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/black-diamond-therapeutics#company-drugs.

• What are the latest developments for Blackmores Institute?

  In the last 12 months our linked public records show 17 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Blackmores Institute focus on?

  Blackmores Institute focuses on Peripheral Artery Disease, Muscle-Invasive Bladder Carcinoma, Therapeutic Equivalency based on our analysis of their pipeline programs and drug development activities.